Gastroparesis Market Insight Epidemiology And Market Forecast

DelveInsight's 'Gastroparesis Market Insights, Epidemiology, and Market Forecast—2028' report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Gastroparesis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan

Study Period: 2017-2028

Gastroparesis—Disease Understanding and Treatment Algorithm

Gastroparesis, which is a translated meaning of “stomach paralysis”, is a digestive disorder characterized by delayed gastric emptying of solid food in the absence of mechanical obstruction of the stomach, resulting in the cardinal symptoms of early satiety, postprandial fullness, nausea, vomiting, belching and bloating. It is now recognized as part of a broader spectrum of gastric neuromuscular dysfunction that includes impaired gastric accommodation. The overlap between the symptoms, of Gastroparesis and other disorders such as functional dyspepsia, makes the diagnosis of Gastroparesis difficult.

According to the American Diabetes Association, Gastroparesis is a disorder affecting people with both type 1 and type 2 diabetes, in which the stomach takes too long to empty its contents (delayed gastric emptying). The vagus nerve controls the movement of food through the digestive tract. If this nerve is damaged or stops working, the muscles of the stomach and intestines do not work normally, and the movement of food is slowed or stopped. Just as with other types of neuropathy, diabetes can damage the vagus nerve if blood glucose levels remain high over a long period. High blood glucose causes chemical changes in nerves and damages the blood vessels that carry oxygen and nutrients to the nerves.

The etiology of Gastroparesis include diabetic, postsurgical, Iatrogenic, surgical and idiopathic as these are major causes of gastroparesis. Based on the causes, Gastroparesis is divided into three major types, i.e., Idiopathic gastroparesis, Diabetic gastroparesis, and Post-surgical gastroparesis. Some of the researchers proposed a classification system to help determine appropriate treatment options such as Grade 1, or mild gastroparesis, is characterized by symptoms that come and go and can easily be controlled by dietary modification and by avoiding medications that slow gastric emptying. Grade 2, or compensated gastroparesis, is characterized by moderately severe symptoms. Individuals with Grade 2 Gastroparesis are treated with medications that stimulate gastric emptying and medications that reduce vomiting; such individuals require hospitalization only infrequently. Grade 3, or gastric failure, is characterized by individuals who do not respond to medications used to treat gastroparesis. These individuals cannot maintain proper nutrition or hydration. Required therapies may include intravenous fluids and medications and nutrition, or surgery. Individuals with Grade 3 Gastroparesis often require hospitalization.

The treatment of Gastroparesis is based on the severity of symptoms of the disease. If diabetes is associated with gastroparesis, then treatment is done by controlling blood glucose levels. The treatment of Gastroparesis mainly includes nonpharmacological steps, such as dietary modification, and pharmacological measures, including medications that stimulate gastric emptying (prokinetics), medications that reduce vomiting (antiemetics), medications for controlling pain and intestinal spasms, and surgery.


Gastroparesis Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalence of Gastroparesis, Gender-Specific Prevalence of Gastroparesis, Severity-Specific Prevalence of Gastroparesis, Type-Specific Prevalence of Gastroparesis, and Total Diagnosed Prevalent Population of Gastroparesis] scenario of Gastroparesis in the 7MM Countries covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2028.

DelveInsight's analysts have assessed that the total prevalent population of Gastroparesis in the 7MM was 33,690,400 in 2017. In addition to this, it was accessed that the total diagnosed prevalent population of Gastroparesis in the 7MM was assessed to be 16,845,200 in 2017.

Gastroparesis Drug Chapters

Gastroparesis is a complex, debilitating dysmotility disorder with challenging symptom management. Given the limited efficacy of treatment options and serious side effects, significant research continues for therapeutic options for Gastroparesis.

The treatment landscape of Gastroparesis comprises of very few pharmacotherapies. The usual treatments for Gastroparesis include nutritional assessment, dietary modifications, and Pharmacological Therapies. Pharmacological therapies include Prokinetic Agents, Antiemetic Agents (off-label), and Antianxiety Benzodiazepine Agents (off-label). Apart from these Pharmacological therapies, Electrical Stimulation Therapies, Endoscopic Therapies, and Surgical Therapies are used for the treatment management of Gastroparesis. The primary aim of present therapies is to improve the efficiency of the gastric pump and to relieve symptoms of nausea, bloating, vomiting, and pain. The selection of recommended drugs is based on the severity of the symptoms (grades).

“According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Metoclopramide, Domperidone, Erythromycin, Antiemetics, Antidepressants, and Pain medicines are helpful for the treatment of Gastroparesis and associated symptoms.”

Gastroparesis Market Outlook

The market size of Gastroparesis in seven major markets (7MM) is estimated to be USD 3,414.16 million in 2017. The United States accounts for the highest market size of Gastroparesis,i.e. USD 1,558.41 million, in comparison to the other major markets i.e., EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Among the EU5 countries, Germany had the highest market size in 2017, while the UK had the lowest market size of Gastroparesis in 2017.


Gastroparesis Drugs Uptake

With the launch of emerging therapies like Gimoti (EVK-001, a product of Evoke Pharma), which is a metoclopramide nasal spray, Relamorelin (Allergan), Tradipitant (Vanda Pharmaceuticals), Velusetrag (Theravance Biopharma), and CIN-102 (Deuterated Domperidone, CinRX Pharma), the market of Gastroparesis is anticipated to change during the forecast period (2019-2028).

Products that are anticipated to be launched during the forecast period are in late clinical stages of development, while others are in ongoing late clinical development stages. Some of the above-mentioned drug candidates have shown very promising results and it has been anticipated by DelveInsight's analysts that completion of clinical development and launch of these products in the market, might increase the market share of these companies, and besides this, patients of Gastroparesis will have better management practices.

According to our assessment, potential emerging candidates shall launch in the upcoming years of the forecast period [2019-2028], and with their anticipated launch, the market size of Gastroparesis will also experience significant growth.

Gastroparesis Report Insights

• Total Prevalence of Gastroparesis

• Gender-Specific Prevalence of Gastroparesis

• Severity-Specific Prevalence of Gastroparesis

• Type-Specific Prevalence of Gastroparesis

• Total Diagnosed Prevalent Population of Gastroparesis

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies

Gastroparesis Report Key Strengths

• 10-Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake

• Highly Analyzed Market

• Key Cross Competition

Gastroparesis Report Assessment

• Current Treatment Practices

• Unmet Needs

• Detailed Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Gastroparesis market

• Organize sales and marketing efforts by identifying the best opportunities for Gastroparesis market

• To understand the future market competition in the Gastroparesis market.

1. Key Insights

2. Gastroparesis: Market Overview at a Glance

2.1. Total Market Share (%) Distribution of Gastroparesis in 2017

2.2. Total Market Share (%) Distribution of Gastroparesis in 2028

3. Gastroparesis: Disease Background and Overview

3.1. Introduction

3.2. Types of Gastroparesis: Based on Causes

3.2.1. Idiopathic Gastroparesis (IG)

3.2.2. Diabetic Gastroparesis (DGp)

3.2.3. Iatrogenic and Postsurgical Gastroparesis

3.3. Clinical Signs and Symptoms

3.4. Mechanisms or Pathophysiology of Gastroparesis

3.5. Diagnosis of Gastroparesis

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. Total Prevalence of Gastroparesis in the 7MM

4.3. Type-Specific Prevalence of Gastroparesis in the 7MM

4.4. Gender-Specific Prevalence of Gastroparesis in the 7MM

4.5. Severity Specific Prevalence of Gastroparesis in the 7MM

4.6. Total Diagnosed Prevalent Population of Gastroparesis in the 7MM

5. United States Epidemiology

5.1. Assumptions and Rationale

5.2. Total Prevalence of Gastroparesis in the United States

5.3. Type-Specific Diagnosed Prevalence of Gastroparesis in the United States

5.4. Gender-Specific Prevalence of Gastroparesis in the United States

5.5. Severity Specific Prevalence of Gastroparesis in the United States

5.6. Total Diagnosed Prevalence of Gastroparesis in the United States

6. EU5 Epidemiology

6.1. Germany Epidemiology

6.1.1. Total Prevalence of Gastroparesis in Germany

6.1.2. Type-Specific Prevalence of Gastroparesis in Germany

6.1.3. Gender-Specific Prevalence of Gastroparesis in Germany

6.1.4. Severity Specific Prevalence of Gastroparesis in Germany

6.1.5. Total Diagnosed Prevalence of Gastroparesis in Germany

6.2. France Epidemiology

6.2.1. Total Prevalence of Gastroparesis in France

6.2.2. Type-Specific Prevalence of Gastroparesis in France

6.2.3. Gender-Specific Prevalence of Gastroparesis in France

6.2.4. Severity Specific Prevalence of Gastroparesis in France

6.2.5. Total Diagnosed Prevalence of Gastroparesis in France

6.3. Italy Epidemiology

6.3.1. Total Prevalence of Gastroparesis in Italy

6.3.2. Type-Specific Prevalence of Gastroparesis in Italy

6.3.3. Gender-Specific Prevalence of Gastroparesis in Italy

6.3.4. Severity Specific Prevalence of Gastroparesis in Italy

6.3.5. Total Diagnosed Prevalence of Gastroparesis in Italy

6.4. Spain Epidemiology

6.4.1. Total Prevalence of Gastroparesis in Spain

6.4.2. Type-Specific Prevalence of Gastroparesis in Spain

6.4.3. Gender-Specific Prevalence of Gastroparesis in Spain

6.4.4. Severity Specific Prevalence of Gastroparesis in Spain

6.4.5. Total Diagnosed Prevalence of Gastroparesis in Spain

6.5. United Kingdom Epidemiology

6.5.1. Total Prevalence of Gastroparesis in the United Kingdom

6.5.2. Type-Specific Prevalence of Gastroparesis in the United Kingdom

6.5.3. Gender-Specific Prevalence of Gastroparesis in the United Kingdom

6.5.4. Severity Specific Prevalence of Gastroparesis in the United Kingdom

6.5.5. Total Diagnosed Prevalence of Gastroparesis in the United Kingdom

7. Japan Epidemiology

7.1. Assumptions and Rationale

7.2. Total Prevalence of Gastroparesis in Japan

7.3. Type-Specific Prevalence of Gastroparesis in Japan

7.4. Gender-Specific Prevalence of Gastroparesis in Japan

7.5. Severity Specific Prevalence of Gastroparesis in Japan

7.6. Total Diagnosed Prevalence of Gastroparesis in Japan

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Treatment Algorithm for Gastroparesis

8.2. Treatment and Management for Gastroparesis

8.2.1. Dietary Modifications

8.2.2. Pharmacological Treatment

8.2.3. Pyloric Intervention

8.2.4. Gastric Electrical Stimulation

9. Proposed Clinical Guidelines for the Management of Gastroparesis

9.1. Recommendations

9.2. Consensus Guidelines for Clinical Management of Diabetic Gastroparesis

10. Unmet Needs

11. Marketed Products

11.1. Reglan: ANI Pharmaceuticals

11.1.1. Product Description

11.1.2. Regulatory Milestones

11.1.3. Product Profile

11.2. Motilium (Domperidone): Janssen

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Safety and Efficacy

11.2.4. Product Profile

12. Emerging Therapies

12.1. Key Cross Competition

12.2. Relamorelin: Allergan

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Product Profile

12.3. Gimoti (Metoclopramide Nasal Spray): Evoke Pharma

12.3.1. Product Description

12.3.2. Other Developmental Activities

12.3.3. Clinical Development

12.3.4. Safety and Efficacy

12.3.5. Product Profile

12.4. Tradipitant: Vanda Pharmaceuticals

12.4.1. Product Description

12.4.2. Other Developmental Activities

12.4.3. Clinical Development

12.4.4. Safety and Efficacy

12.4.5. Product Profile

12.5. Velusetrag: Theravance Biopharma

12.5.1. Product Description

12.5.2. Other Developmental Activities

12.5.3. Clinical Development

12.5.4. Safety and Efficacy

12.5.5. Product Profile

12.6. CNSA-001: Censa Pharmaceuticals

12.6.1. Product Description

12.6.2. Clinical Development

12.6.3. Product Profile

12.7. Nimacimab: Bird Rock Bio

12.7.1. Product Description

12.7.2. Other Development Activities

12.7.3. Clinical Development

12.7.4. Product Profile

12.8. CIN-102: CinDome Pharma

12.8.1. Product Description

12.8.2. Other Developmental Activities

12.8.3. Clinical Development

12.8.4. Safety and Efficacy

12.8.5. Product Profile

12.9. TAK 906: Takeda (Millennium Pharmaceuticals)

12.9.1. Product Description

12.9.2. Other Developmental Activities

12.9.3. Clinical Development

12.9.4. Safety and Efficacy

12.9.5. Product Profile

13. Gastroparesis: Seven Major Market Analysis

13.1. Key Findings

13.2. Market Size of Gastroparesis in 7MM

13.3. Market Size of Gastroparesis by Therapies in the 7MM

14. United States: Market Outlook

14.1. United States Market Size

14.1.1. Total Market size of Gastroparesis in the United States

14.1.2. Market Size of Gastroparesis by Therapies in the US

15. EU-5 countries: Market Outlook

15.1. Germany Market Size

15.1.1. Total Market size of Gastroparesis in Germany

15.1.2. Market Size of Gastroparesis by therapies in Germany

15.2. France Market Size

15.2.1. Total Market size of Gastroparesis in France

15.2.2. Market Size of Gastroparesis by therapies in France

15.3. Italy Market Size

15.3.1. Total Market size of Gastroparesis in Italy

15.3.2. Market Size of Gastroparesis by therapies in Italy

15.4. Spain Market Size

15.4.1. Total Market size of Gastroparesis in Spain

15.4.2. Market Size of Gastroparesis by therapies in Spain

15.5. United Kingdom Market Size

15.5.1. Total Market size of Gastroparesis in the United Kingdom

15.5.2. Market Size of Gastroparesis by therapies in the UK

16. Japan Market Outlook

16.1. Japan Market Size

16.1.1. Total Market size of Gastroparesis in Japan

16.1.2. Market Size of Gastroparesis by therapies in Japan

17. Market Drivers

18. Market Barriers

19. Appendix

19.1. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

Table 1 Pathogenesis and Etiology of Gastroparesis

Table 2 Total Prevalence of Gastroparesis in the 7MM (2017-2028)

Table 3 Type-Specific Prevalence of Gastroparesis in the 7MM (2017-2028)

Table 4 Gender-Specific Prevalence of Gastroparesis in the 7MM (2017-2028)

Table 5 Severity-Specific Prevalence of Gastroparesis in the 7MM (2017-2028)

Table 6 Total Diagnosed Prevalent Population of Gastroparesis in the 7MM (2017-2028)

Table 7 Total Prevalence of Gastroparesis in the United States (2017-2028)

Table 8 Type-Specific Diagnosed Prevalence of Gastroparesis in the United States (2017-2028)

Table 9 Gender-Specific Prevalence of Gastroparesis in the US (2017-2028)

Table 10 Severity-Specific Prevalence of Gastroparesis in the United States(2017-2028)

Table 11 Total Diagnosed Prevalence of Gastroparesis in the United States (2017-2028)

Table 12 Total Prevalence of Gastroparesis in Germany (2017-2028)

Table 13 Type-Specific Prevalence of Gastroparesis in Germany (2017-2028)

Table 14 Gender-Specific Prevalence of Gastroparesis in Germany (2017-2028)

Table 15 Severity-Specific Prevalence of Gastroparesis in Germany (2017-2028)

Table 16 Total Diagnosed Prevalence of Gastroparesis in Germany (2017-2028)

Table 17 Total Prevalence of Gastroparesis in France (2017-2028)

Table 18 Type-Specific Prevalence of Gastroparesis in France (2017-2028)

Table 19 Gender-Specific Prevalence of Gastroparesis in France (2017-2028)

Table 20 Severity-Specific Prevalence of Gastroparesis in France (2017-2028)

Table 21 Total Diagnosed Prevalence of Gastroparesis in France (2017-2028)

Table 22 Total Prevalence of Gastroparesis in Italy (2017-2028)

Table 23 Type-Specific Prevalence of Gastroparesis in Italy (2017-2028)

Table 24 Gender-Specific Prevalence of Gastroparesis in Italy (2017-2028)

Table 25 Severity-Specific Prevalence of Gastroparesis in Italy (2017-2028)

Table 26 Total Diagnosed Prevalence of Gastroparesis in Italy (2017-2028)

Table 27 Total Prevalence of Gastroparesis in Spain (2017-2028)

Table 28 Type-Specific Prevalence of Gastroparesis in Spain (2017-2028)

Table 29 Gender-Specific Prevalence of Gastroparesis in Spain (2017-2028)

Table 30 Severity-Specific Prevalence of Gastroparesis in Spain (2017-2028)

Table 31 Total Diagnosed Prevalence of Gastroparesis in Spain (2017-2028)

Table 32 Total Prevalence of Gastroparesis in the United Kingdom (2017-2028)

Table 33 Type-Specific Prevalence of Gastroparesis in the United Kingdom (2017-2028)

Table 34 Gender-Specific Prevalence of Gastroparesis in the United Kingdom (2017-2028)

Table 35 Severity-Specific Prevalence of Gastroparesis in the United Kingdom (2017-2028)

Table 36 Total Diagnosed Prevalence of Gastroparesis in the United Kingdom (2017-2028)

Table 37 Total Prevalence of Gastroparesis in Japan (2017-2028)

Table 38 Type-Specific Prevalence of Gastroparesis in Japan (2017-2028)

Table 39 Gender-Specific Prevalence of Gastroparesis in Japan (2017-2028)

Table 40 Severity-Specific Prevalence of Gastroparesis in Japan (2017-2028)

Table 41 Total Diagnosed Prevalence of Gastroparesis in Japan (2017-2028)

Table 42 Pharmacological Treatment Options for the Management of Diabetic Gastroparesis

Table 43 Pharmacological Treatment Options for the Management of Diabetic Gastroparesis

Table 44 Pharmacological Treatment Options for the Management of Diabetic Gastroparesis

Table 45 Emerging Keycross Competition

Table 46 Relamorelin (RM-131), Clinical Trial Description, 2019

Table 47 Metoclopramide Nasal Spray; Clinical Trial Description, 2019

Table 48 Tradipitant; Clinical Trial Description, 2019

Table 49 Velusetrag; Clinical Trial Description, 2019

Table 50 CNSA-001, Clinical Trial Description, 2019

Table 51 Nimacimab, Clinical Trial Description, 2019

Table 52 CIN-102, Clinical Trial Description, 2019

Table 53 TAK 906, Clinical Trial Description, 2019

Table 54 Market Size of Gastroparesis in 7MM in USD Million (2017-2028)

Table 55 Market Size of Gastroparesis by therapies in the 7MM, in USD Million (2017-2028)

Table 56 Currently Prescribed Classes and their Side-Effects

Table 57 Emerging Therapies Expected to be Launched During Forecast Period (2019-2028) in the United States

Table 58 The US Market Size of Gastroparesis in USD Million (2017-2028)

Table 59 Market Size of Gastroparesis by therapies in the US, in USD Million (2017-2028)

Table 60 Germany Market Size of Gastroparesis in USD Million (2017-2028)

Table 61 Market Size of Gastroparesis by therapies in Germany, in USD Million (2017-2028)

Table 62 France Market Size of Gastropares is in USD Million (2017-2028)

Table 63 Market Size of Gastroparesis by therapies in France, in USD Million (2017-2028)

Table 64 Italy Market Size of Gastroparesis in USD Million (2017-2028)

Table 65 Market Size of Gastroparesis by therapies in Italy, in USD Million (2017-2028)

Table 66 Spain Market Size of Gastroparesis in USD Million (2017-2028)

Table 67 Market Size of Gastroparesis by therapies in Spain, in USD Million (2017-2028)

Table 68 The UK Market Size of Gastroparesis in USD Million (2017-2028)

Table 69 Market Size of Gastroparesis by therapies in the UK, in USD Million (2017-2028)

Table 70 Japan Market Size of Gastroparesis in USD Million (2017-2028)

Table 71 Market Size of Gastroparesis by therapies in Japan, in USD Million (2017-2028)

Figure 1 Types of Gastroparesis Based on Causes

Figure 2 Etiologies of Gastroparesis

Figure 3 Interaction of Interstitial Cells of Cajal (ICC) Cells and Neuronal Nitric Oxide Synthase (nNOS) Signaling for Normal Gastric Emptying (GE)

Figure 4 Mechanisms of Gastric Accommodation and Emptying

Figure 5 Diagnosis of Gastroparesis

Figure 6 Total Prevalence of Gastroparesis in the 7MM (2017-2028)

Figure 7 Type-Specific Prevalence of Gastroparesis in the 7MM (2017-2028)

Figure 8 Gender- Specific Prevalence of Gastroparesis in the 7MM(2017-2028)

Figure 9 Severity-Specific Prevalence of Gastroparesis in the 7MM (2017-2028)

Figure 10 Total Diagnosed Prevalent Population of Gastroparesis in the 7MM (2017-2028)

Figure 11 Total Prevalence of Gastroparesis in the United States (2017-2028)

Figure 12 Type-Specific Diagnosed Prevalence of Gastroparesis in the United States (2017-2028)

Figure 13 Gender- Specific Prevalence of Gastroparesisin the US (2017-2028)

Figure 14 Severity-Specific Prevalence of Gastroparesis in the United States (2017-2028)

Figure 15 Total Diagnosed Prevalence of Gastroparesis in the United States (2017-2028)

Figure 16 Total Prevalence of Gastroparesis in Germany (2017-2028)

Figure 17 Type-Specific Prevalence of Gastroparesis in Germany (2017-2028)

Figure 18 Gender- Specific Prevalence of Gastroparesis in Germany (2017-2028)

Figure 19 Severity-Specific Prevalence of Gastroparesis in Germany (2017-2028)

Figure 20 Total Diagnosed Prevalence of Gastroparesis in Germany (2017-2028)

Figure 21 Total Prevalence of Gastroparesis in France (2017-2028)

Figure 22 Type-Specific Prevalence of Gastroparesis in France (2017-2028)

Figure 23 Gender- Specific Prevalence of Gastroparesis in France (2017-2028)

Figure 24 Severity-Specific Prevalence of Gastroparesis in France (2017-2028)

Figure 25 Total Diagnosed Prevalence of Gastroparesis in France (2017-2028)

Figure 26 Total Prevalence of Gastroparesis in Italy (2017-2028)

Figure 27 Type-Specific Prevalence of Gastroparesis in Italy (2017-2028)

Figure 28 Gender- Specific Prevalence of Gastroparesis in Italy (2017-2028)

Figure 29 Severity-Specific Prevalence of Gastroparesis in Italy (2017-2028)

Figure 30 Total Diagnosed Prevalence of Gastroparesis in Italy (2017-2028)

Figure 31 Total Prevalence of Gastroparesis in Spain (2017-2028)

Figure 32 Type-Specific Prevalence of Gastroparesis in Spain (2017-2028)

Figure 33 Gender- Specific Prevalence of Gastroparesis in Spain (2017-2028)

Figure 34 Severity-Specific Prevalence of Gastroparesis in Spain (2017-2028)

Figure 35 Total Diagnosed Prevalence of Gastroparesis in Spain (2017-2028)

Figure 36 Total Prevalence of Gastroparesis in the United Kingdom (2017-2028)

Figure 37 Type-Specific Prevalence of Gastroparesis in the United Kingdom (2017-2028)

Figure 38 Gender- Specific Prevalence of Gastroparesis in the United Kingdom (2017-2028)

Figure 39 Severity-Specific Prevalence of Gastroparesis in the United Kingdom (2017-2028)

Figure 40 Total Diagnosed Prevalence of Gastroparesis in the United Kingdom (2017-2028)

Figure 41 Total Prevalence of Gastroparesis in Japan (2017-2028)

Figure 42 Type-Specific Prevalence of Gastroparesis in Japan (2017-2028)

Figure 43 Gender- Specific Prevalence of Gastroparesis in Japan (2017-2028)

Figure 44 Severity-Specific Prevalence of Gastroparesis in Japan (2017-2028)

Figure 45 Total Diagnosed Prevalence of Gastroparesis in Japan (2017-2028)

Figure 46 Diagnosis and Management Algorithm for Gastroparesis Syndromes

Figure 47 Algorithm for Prokinetic Therapy in Gastroparesis

Figure 48 Treatment Algorithm for Gastroparesis

Figure 49 Unmet Needs of Gastroparesis

Figure 50 Potential Drug-drug Interactions in Gastroparesis

Figure 51 Market Size of Gastroparesis in the 7MM in USD Million (2017-2028)

Figure 52 Market Size of Gastroparesis by therapies in the 7MM, in USD Million (2017-2028)

Figure 53 Market Size of Gastroparesis in the US, USD Millions (2017-2028)

Figure 54 Market Size of Gastroparesis by therapies in the United States, in USD Million (2017-2028)

Figure 55 Market Size of Gastroparesis in Germany, USD Millions (2017-2028)

Figure 56 Market Size of Gastroparesis by therapies in Germany, in USD Million (2017-2028)

Figure 57 Market Size of Gastroparesis in France, USD Millions (2017-2028)

Figure 58 Market Size of Gastroparesis by therapies in France, in USD Million (2017-2028)

Figure 59 Market Size of Gastroparesis in Italy, USD Millions (2017-2028)

Figure 60 Market Size of Gastroparesis by therapies in Italy in USD Million (2017-2028)

Figure 61 Market Size of Gastroparesis in Spain, USD Millions (2017-2028)

Figure 62 Market Size of Gastroparesis by therapies in Spain in USD Million (2017-2028)

Figure 63 Market Size of Gastroparesis in the UK, USD Millions (2017-2028)

Figure 64 Market Size of Gastroparesis by therapies in the UK in USD Million (2017-2028)

Figure 65 Market Size of Gastroparesis in Japan, USD Millions (2017-2028)

Figure 66 Market Size of Gastroparesis by therapies in Japan in USD Million (2017-2028)

Figure 67 Market Drivers

Figure 68 Market Barriers

  • Tags:
  • Gastroparesis market
  • Gastroparesis market research
  • Gastroparesis market insight
  • Gastroparesis market trends
  • Gastroparesis market forecast
  • Gastroparesis market share
  • Gastroparesis pipeline drugs
  • Gastroparesis treatment algorithm
  • Gastroparesis drugs
  • Gastroparesis sales forecasting
  • Gastroparesis market size
  • Gastroparesis disease
  • Gastroparesis epidemiology
  • Gastroparesis
  • Gastroparesis Companies
  • Gastroparesis Pipeline

Forward to Friend

Need A Quote